<![CDATA[Pharco Pharmaceuticals, Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=26036>Mon, 04 May 2026 19:21:33 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Pharco Pharmaceuticals Inc. Reports Ravidasvir Achieved 100% Cure Rate to Date When Combined with Sofosbuvir for HCV, Non-Cirrhotic, Genotype 4 Patients]]>https://www.newswire.co.kr/newsRead.php?no=809859Tue, 17 Nov 2015 10:50:00 +0900<![CDATA[파코 파마슈티컬스 발표: HCV 비경변 유전자형 4형 환자에 대한 라비다스비르- 소포스부비르 병용으로 현재까지 100% 치료율 달성]]>https://www.newswire.co.kr/newsRead.php?no=809860Tue, 17 Nov 2015 10:50:00 +0900<![CDATA[Pharco Pharmaceuticals, Inc. Announces Late-Breaker Oral Presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2015]]>https://www.newswire.co.kr/newsRead.php?no=808704Thu, 05 Nov 2015 13:10:00 +0900<![CDATA[파코 파마슈티컬스, ‘2015년 미국간학회(AASLD) 연례 학술대회’서 최신혁신연구 구두 발표]]>https://www.newswire.co.kr/newsRead.php?no=808705Thu, 05 Nov 2015 13:10:00 +0900